Catalysts / CGEM
Upcoming FDA decisions and readouts we track for Cullinan Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Cullinan Therapeutics (CGEM, listed on Nasdaq). It concerns Zipalertinib (EGFR exon 20 insertion NSCLC, second line).
First on the list: the PDUFA date for Zipalertinib (EGFR exon 20 insertion NSCLC, second line), dated 27 Feb 2027.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Cullinan Therapeutics CGEM · Nasdaq | Zipalertinib | EGFR exon 20 insertion NSCLC, second line | 27 Feb 2027 in 143d |
PDUFA date | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList